Furthermore, gene expression analysis of vemurafenib-treated BRAF mutated U266 cells revealed that the blockade of BRAF activation was accompanied by changes in the expression levels of critical genes for myeloma cells, such as TP53, or IL-6 and MM proliferation-associated genes [20] (respectively up- and down-regulated following treatment). The gene discussed is TP53; the disease is Miyoshi myopathy.